metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	atezolizumab plus bevacizumab
	IMmotion-151 (all population), 2019 Lancet 2019; 393:2404-2415 Clin Cancer Res 2020; 26:2506-2514 NCT02420821	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	atezolizumab plus bevacizumab	Sunitinib	patients with unresectable locally advanced or metastatic renal cell carcinoma with any component of clear cell or sarcomatoid histology, with Karnofsky performance status 70% or higher.	454 / 461	high	inconclusive
	IMmotion-150 (AtB - all population), 2018 Nat. Med. 2018; 24:749-757 BJU Int 2020 Jul;126(1):73-82. NCT01984242	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	atezolizumab with bevacizumab	sunitinib	unresectable advanced or mRCC with a component of clear cell histology and/or sarcomatoid histology not previously treated with any systemic agents for RCC	101 / 101	some concern	inconclusive
mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative
versus sunitinib
	atezolizumab plus bevacizumab
	IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019 Lancet 2019; 393:2404-2415 Clin Cancer Res 2020; 26:2506-2514 NCT02420821	RCT	mRCC - L1 - PDL1 negative	atezolizumab plus bevacizumab	Sunitinib	Patients with unresectable locally advanced or metastatic renal cell carcinoma with any component of clear cell or sarcomatoid histology (PDL1 negative patients)	276 / 277	high	inconclusive
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
versus sunitinib
	atezolizumab plus bevacizumab
	IMmotion-151 (PDL1 >1%), 2019 Lancet 2019; 393:2404-2415 Clin Cancer Res 2020; 26:2506-2514 NCT02420821	RCT	mRCC - L1 - PDL1 positive	atezolizumab plus bevacizumab	Sunitinib	patients with unresectable locally advanced or metastatic renal cell carcinoma with any component of clear cell or sarcomatoid histology	178 / 184	high	inconclusive
	IMmotion-150 (AtB - PDL1>1%), 2018 Nat. Med. 2018; 24:749-757 BJU Int 2020 Jul;126(1):73-82. NCT01984242	RCT	mRCC - L1 - PDL1 positive	atezolizumab with bevacizumab	sunitinib	unresectable advanced or mRCC with a component of clear cell histology and/or sarcomatoid histology not previously treated with any systemic agents for RCC. patients with PDL1 >1% positive only	50 / 60	some concern	suggested